Abstract
Since their proposal in 1976, sigma (σ) receptors have been increasingly implicated in the pathophysiology of virtually all major central nervous system (CNS) disorders, including anxiety, depression, schizophrenia, and drug addiction. Due to their involvement in motor function and higher cognitive function,σ receptors have also been implicated in movement disorders (such as Parkinson's disease) and memory deficits (including Alzheimer's disease). In most cases the precise mechanism(s) linking σ receptors to CNS disease are unknown or yet to be fully elucidated. However, many σ ligands have shown promise in pharmacological studies and animal models of the aforementioned diseases, and some have entered clinical trials. This review will assess the validity of σ receptors as a target for various CNS diseases based on evidence from animal models of human diseases, preclinical studies in humans, and full clinical trials.
Keywords: Sigma receptor, central nervous system, schizophrenia, anxiety, depression, Alzheimer's disease, addiction, pain, clinical trials, tumor cells
Current Pharmaceutical Design
Title: The Therapeutic Potential of Sigma (σ) Receptors for the Treatment of Central Nervous System Diseases: Evaluation of the Evidence
Volume: 18 Issue: 7
Author(s): Samuel D. Banister and Michael Kassiou
Affiliation:
Keywords: Sigma receptor, central nervous system, schizophrenia, anxiety, depression, Alzheimer's disease, addiction, pain, clinical trials, tumor cells
Abstract: Since their proposal in 1976, sigma (σ) receptors have been increasingly implicated in the pathophysiology of virtually all major central nervous system (CNS) disorders, including anxiety, depression, schizophrenia, and drug addiction. Due to their involvement in motor function and higher cognitive function,σ receptors have also been implicated in movement disorders (such as Parkinson's disease) and memory deficits (including Alzheimer's disease). In most cases the precise mechanism(s) linking σ receptors to CNS disease are unknown or yet to be fully elucidated. However, many σ ligands have shown promise in pharmacological studies and animal models of the aforementioned diseases, and some have entered clinical trials. This review will assess the validity of σ receptors as a target for various CNS diseases based on evidence from animal models of human diseases, preclinical studies in humans, and full clinical trials.
Export Options
About this article
Cite this article as:
D. Banister Samuel and Kassiou Michael, The Therapeutic Potential of Sigma (σ) Receptors for the Treatment of Central Nervous System Diseases: Evaluation of the Evidence, Current Pharmaceutical Design 2012; 18 (7) . https://dx.doi.org/10.2174/138161212799436539
DOI https://dx.doi.org/10.2174/138161212799436539 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Oxycodone/Naloxone in the Management of Patients with Pain and Opioid–Induced Bowel Dysfunction
Current Drug Targets NMR Studies on How the Binding Complex of Polyisoprenol Recognition Sequence Peptides and Polyisoprenols Can Modulate Membrane Structure
Current Protein & Peptide Science T-Type Calcium Channels and Thalamocortical Rhythms in Sleep: A Perspective from Studies of T-Type Calcium Channel Knockout Mice
CNS & Neurological Disorders - Drug Targets Pharmacokinetic Evaluation of Callistemon viminalis Derived Natural Compounds as Targeted Inhibitors Against δ -Opioid Receptor and Farnesyl Transferase
Letters in Drug Design & Discovery The Interaction of Dietary Fibres with the Colon
Current Nutrition & Food Science The Risk That DSM-5 Will Further Inflate the Diagnostic Bubble
Current Psychiatry Reviews An Updated Patent Therapeutic Agents Targeting MMPs
Recent Patents on Anti-Cancer Drug Discovery Antipsychotic Medications in the Treatment of Bipolar Disorder
Current Drug Targets Inhibition of Brain Ischemia-Caused Notch Activation in Microglia May Contribute to Isoflurane Postconditioning-Induced Neuroprotection in Male Rats
CNS & Neurological Disorders - Drug Targets Amyloid PET and MRI in Alzheimers Disease and Mild Cognitive Impairment
Current Alzheimer Research Comparison of Status Epilepticus Models Induced by Pilocarpine and Nerve Agents - A Systematic Review of the Underlying Aetiology and Adopted Therapeutic Approaches
Current Medicinal Chemistry Simulation Modeling of Supported Lipid Membranes – A Review
Current Topics in Medicinal Chemistry Small-molecule Modulation of HDAC6 Activity: The Propitious Therapeutic Strategy to Vanquish Neurodegenerative Disorders
Current Medicinal Chemistry Recent Advances in Delivery Through the Blood-Brain Barrier
Current Topics in Medicinal Chemistry Role of Monocarboxylate Transporters in Drug Delivery to the Brain
Current Pharmaceutical Design Editorial [Hot Topic: QSAR Models for Computer-Aided Drug Design and Molecular Docking for Disorders of the Central Nervous System and Other Diseases]
Current Topics in Medicinal Chemistry COMMENTARY: Magnetic Resonance Techniques Applied to Parkinson’s Disease
CNS & Neurological Disorders - Drug Targets Non-Small Cell Lung Carcinoma: An Overview on Targeted Therapy
Current Drug Targets Stimuli-responsive Polymeric Nanosystems for Therapeutic Applications
Current Pharmaceutical Design Bowel Habit in Preterm New borns: Effect of New Formulas
Endocrine, Metabolic & Immune Disorders - Drug Targets